Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
8-K
Dilutive issuance
confidence 85%
filed 2026-09-14
Item 8.01
This disclosure describes a public offering of 2,337,323 shares of common stock by selling stockholders, plus an additional 350,598 shares from an exercised underwriter option, totaling approximately 2.7 million shares. Although the Company itself did not receive proceeds (the selling stockholders did), this represents a material dilutive issuance of equity that increases the share count and dilutes existing shareholders. The transaction is structured as a registered public offering under an effective S-3 shelf registration, which is a standard mechanism for dilutive equity issuances material to investors.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 85%
filed 2026-09-14
Item 8.01
The disclosure reports the exercise of 53.1 million common stock warrants issued in June 2025, resulting in approximately $128.2 million in aggregate gross proceeds through the September 12, 2026 expiration date. While technically a warrant exercise rather than a new issuance, this represents a material dilutive capital event that increased the company's equity base and raised substantial cash. The magnitude ($128.2 million) and the concentration of exercises in the final quarter (46 million warrants, $115 million) indicate material shareholder dilution and capital activity warranting disclosure.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 75%
filed 2026-09-14
Item 8.01
The Company announced establishment of a $300 million at-the-market (ATM) offering program for Variable Rate Series C Perpetual Preferred Stock (CHAD), with net proceeds intended to fund additional SOL purchases. While the ATM program does not represent an immediate capital raise and the Company is not obligated to sell shares, the establishment of a $300 million equity issuance capacity is a material dilutive financing event that would affect investor assessment of capital structure and ownership dilution. The press release emphasizes this as a new "funding engine" and "capital flywheel" mechanism.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 85%
filed 2026-09-14
Item 3.02
Future Vision II Acquisition Corp. disclosed unregistered sales of equity securities, including Units and underlying securities issuable upon conversion of a Note to the Sponsor. The convertible securities with registration rights and transfer restrictions constitute a dilutive private placement affecting ownership and capital structure ahead of the SPAC's business combination.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 92%
filed 2026-09-11
EX-99.1
TORM plc announced a capital increase of 31,483 Class A shares resulting from the exercise of Restricted Share Units (RSUs) as part of its incentive program. The new shares were subscribed for in cash at DKK 179.80 per share, increasing total share capital to USD 1,024,212.67 (102,421,267 A-shares). This represents a dilutive equity issuance tied to employee compensation, which is material to investors assessing ownership dilution and capital structure changes.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 95%
filed 2026-09-11
EuroDry entered into an Equity Distribution Agreement with A.G.P./Alliance Global Partners on September 11, 2026, authorizing the sale of up to $20,000,000 of common shares through an at-the-market (ATM) offering. This is a dilutive equity issuance that would materially affect existing shareholders' ownership and is incorporated into the Company's effective Form F-3 registration statement, signaling an imminent or ongoing capital raise.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 92%
filed 2026-09-11
EX-99.1
The exhibit announces the closing of a partial exercise of the underwriters' over-allotment option in connection with Londian Wason's IPO, resulting in the sale of 626,104 additional ADSs at $22.00 per ADS and aggregate gross proceeds of $108,059,996. This is a dilutive equity issuance that increases the company's share count and raises capital, which is material to investors assessing the registrant's capitalization and ownership structure.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 89%
filed 2026-09-11
Item 1.01
Rent the Runway entered into a rights offering backstop agreement on September 11, 2026, to raise $15,000,000 through an unregistered offering of Class A Common Stock. Existing shareholders will receive pro rata subscription rights, with the Investor Group (CHS, Nexus, and STORY3) committed to backstop all unsubscribed shares at a subscription price of at least $3.55 per share.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 92%
filed 2026-09-11
EX-99.1
This exhibit announces the completion of a public offering of 4,400,000 new common shares of Star Bulk Carriers Corp. at €24.50 per share (approximately US$28.40), raising approximately €107.8 million in gross proceeds. The offering was oversubscribed over 6 times and included both qualified and retail investors. This is a material dilutive equity issuance that increases the company's share count and affects existing shareholders' ownership percentages.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-09-11
Item 3.02
The Company issued 8,529,412 restricted common shares to officers and employees in lieu of $1.45 million in cash bonuses, representing a dilutive unregistered equity issuance exempt under Section 4(a)(2). The substantial share count and conversion of cash compensation to equity is material to investors assessing capital structure and shareholder dilution, particularly at a small-cap issuer (Nasdaq Capital Market listing).
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 85%
filed 2026-09-11
Oklo Inc. entered into an equity distribution agreement on September 11, 2026, authorizing an "at the market" offering of up to $1,000,000,000 in Class A common stock through ten sales agents. This is a dilutive equity issuance that provides the company with significant capital-raising capacity. While the filing also discloses termination of a prior sales agreement (Item 1.02), the principal material event is the new $1 billion ATM offering program, which is material to investors assessing potential shareholder dilution and the company's capital strategy.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 94%
filed 2026-09-11
Item 1.01
Centrus Energy entered into an underwriting agreement on September 9, 2026, to conduct a registered public offering of 500,000 shares of Class A common stock, 2,005,513 pre-funded warrants, and 6,992,382 common warrants, with gross proceeds of approximately $500 million. The offering was priced and is expected to close on September 11, 2026, with proceeds intended for general working capital, technology development, debt repayment, and potential acquisitions.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-09-11
Item 8.01
The Fund announced approval of a transferable rights offering allowing existing shareholders to subscribe for new Common Shares at a discount to market price (92.5% of average closing price or NAV). This is a dilutive equity issuance that will increase the share count and potentially dilute existing shareholders' ownership unless they fully exercise their rights. The offering seeks to raise capital for investment purposes and is material to investors' assessment of ownership dilution and capital structure.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 65%
filed 2026-09-11
The disclosure describes settlement of a forward purchase agreement whereby Harraden Circle entities purchased 5,000,000 Class A shares of CAEP (later exchanged for Company ordinary shares in a business combination) and on September 10, 2026 returned 4,997,030 shares to the Company for cancellation while selling only 2,970 shares on the open market. This represents a material capital transaction involving the issuance and subsequent cancellation of a large block of equity securities; while the net effect is a reduction in shares outstanding, the forward purchase mechanism and the scale of the transaction (5 million shares) are material to investors' understanding of the Company's capitalization and the terms of the CAEP business combination.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-09-11
Item 3.02
Karyopharm issued unregistered Convertible Preferred Stock in a private placement to accredited investors in reliance on Section 4(a)(2) exemption, representing a material financing event affecting the company's capital structure and shareholder dilution.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-09-11
Item 3.02
The Company disclosed the sale of 22,973 Class D Common Shares for $635,000 under a continuous private placement offering of up to $2.165 billion in unregistered equity securities pursuant to Section 4(a)(2) and Regulation D Rule 506(c). This is a classic dilutive issuance of unregistered equity securities, which is material to investors as it increases share count and signals capital-raising activity typical of small- and mid-cap REITs.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 90%
filed 2026-09-11
Item 1.01
Hagerty completed a secondary offering of 10,637,500 shares of Class A common stock (including full exercise of underwriters' option) at $11.95 per share on September 11, 2026. Although the Selling Stockholder (Hagerty Holding Corp., affiliated with the Kim Hagerty Revocable Trust) received the proceeds rather than the Company, the offering materially dilutes existing shareholders by increasing total shares outstanding.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 75%
filed 2026-09-11
Item 8.01
The disclosure describes an underwritten offering of 22.25 million shares of common stock by selling stockholders, with the Company purchasing 2 million shares from the underwriter. Although the Company itself did not receive proceeds (the selling stockholders did), the offering results in dilution to existing shareholders through the issuance of new shares into the market. The Company's repurchase of 2 million shares partially offsets this dilution but does not eliminate the material dilutive effect of the 22.25 million share offering. This is a material capital event affecting share count and ownership structure.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-09-11
Item 3.02
Korsana completed a $380 million private placement of common stock and pre-funded warrants (140.5 million shares and 20.2 million pre-funded warrants) immediately prior to the merger closing, offered to accredited investors in reliance on Section 4(a)(2) of the Securities Act. This materially affects the combined company's post-transaction ownership structure and capitalization.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-09-11
Item 8.01
Corning entered into an Equity Distribution Agreement with Goldman Sachs on September 11, 2026, to sell up to $2 billion of common stock through an "at the market" equity offering program. This is a material dilutive issuance of equity securities under an ATM offering arrangement, which signals potential capital raising and shareholder dilution. The magnitude ($2 billion) and structure (ATM program with a major investment bank) are material to investors assessing the company's capital strategy and equity structure.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 95%
filed 2026-09-11
The 6-K discloses entry into an at-the-market (ATM) sales agreement on September 8, 2026, permitting the Company to offer and sell up to $200 million of Class A ordinary shares through Chaince Securities as sales agent. This is a dilutive equity issuance under a shelf registration (Form F-3), representing a material capital-raising event that would affect investor assessment of share dilution and the registrant's financing strategy.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-09-11
Item 3.02
Sphere 3D entered into a Securities Purchase Agreement on September 8, 2026, for a private placement of 1,666,661 units (each consisting of one common share and one five-year warrant at $3.50 exercise price) for $5.0 million ($3.00 per unit) to accredited investors under Section 4(a)(2) exemption. The placement represents a 29% premium to the closing price on September 4, 2026, with meaningful insider participation including the Chairman and CEO, and includes a six-month lock-up provision; proceeds are designated for working capital and general corporate purposes including AI/HPC development.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 85%
filed 2026-09-11
The Company entered into an advisory agreement on September 11, 2026, under which it will issue 6,000,000 Class B ordinary shares to YITONG ASIA INVESTMENT PTE. LTD. as consideration for advisory services. This constitutes an unregistered equity issuance (private placement) that dilutes existing shareholders. The 12-month lock-up on the Advisor's shares and the strategic nature of the advisory services (corporate strategy, capital markets, investments, M&A) indicate this is a material capital event affecting shareholder equity.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 85%
filed 2026-09-11
The Company entered into a new subscription agreement on September 7, 2026, whereby Beverly Holding Limited (controlled by CEO Muchun Zhu) agreed to subscribe for 1,625,000 Class B ordinary shares at US$0.40 per share for an aggregate of US$650,000. This is an unregistered equity issuance to a related party (the CEO's entity), which constitutes a dilutive issuance. The prior subscription agreement was terminated on September 10, 2026, and replaced with this new one, indicating a material capital transaction requiring disclosure.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 92%
filed 2026-09-11
Safe Bulkers announced the issuance and admission to trading of 12,000,000 new shares of common stock (approximately 10.5% dilution to the existing 113.8 million shares) through a private placement via accelerated bookbuilding. The announcement explicitly states the New Shares were "issued pursuant to a private placement" and will commence trading on Euronext Athens on September 14, 2026. This is a material dilutive equity issuance that would affect a reasonable investor's assessment of ownership and earnings per share.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 90%
filed 2026-09-11
Item 1.01
HNO International issued a convertible redeemable note with $210,000 principal amount and $21,000 original issue discount to CFI Capital LLC, convertible into common stock at 60% of the lowest trading price over 20 days with further potential discounts, with the company reserving 49,295,775 shares for conversion. This dilutive issuance structure includes a most-favored-nation clause and aggressive conversion terms that materially increase dilution risk to existing shareholders.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-09-11
The filing discloses a private placement (PIPE) of Series B Convertible Preferred Stock and warrants completed on September 11, 2026, raising $2,549,900 in gross proceeds at the Subsequent Closing. The securities were issued in reliance on Section 4(a)(2) and Regulation D Rule 506(b), and the preferred stock is convertible into common shares at $0.70 per share, with warrants exercisable at $0.825 and $0.95 per share. This is a classic dilutive unregistered equity issuance to accredited investors, material to shareholders due to the significant dilution and the company's prior delisting risk that this capital raise was designed to address.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 95%
filed 2026-09-11
Park Ha Biological Technology entered into a securities purchase agreement on September 11, 2026, to issue 1,080,000 Class A ordinary shares at $2.75 per share plus warrants to purchase 1,845,452 additional Class A ordinary shares, generating approximately $2.97 million in gross proceeds. This is a classic private investment in public equity (PIPE) transaction involving unregistered equity securities sold to non-U.S. investors under Regulation S, which is a material dilutive issuance requiring disclosure under Item 3.02 of Form 8-K (or equivalent 6-K disclosure).
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-09-11
NewHydrogen entered into an Equity Financing Agreement with GHS Investments on September 8, 2026, providing up to $3,000,000 in funding through a put arrangement where the Company can deliver puts to GHS for purchase of common stock at 92.5% of the lowest traded price over the preceding ten trading days. The Company immediately issued 980,713 restricted shares (0.5% of the commitment amount) as commitment shares. This is a classic dilutive equity issuance structure—a PIPE-like arrangement with registration rights—that raises capital through equity dilution rather than debt, materially affecting shareholder ownership and voting power.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 95%
filed 2026-09-11
MKDWELL Tech Inc. entered into an At the Market Offering Agreement on September 11, 2026, authorizing the sale of up to $100 million in ordinary shares through Maxim Group LLC as sales agent. This is a classic ATM offering—an unregistered equity issuance program that creates dilution risk for existing shareholders. The $100 million aggregate offering price and the discretionary nature of the sales (the Company may offer shares "from time to time at its sole discretion") are material capital-raising events that would affect a reasonable investor's assessment of ownership dilution and the registrant's financing strategy.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-09-11
Banzai International entered into a Securities Purchase Agreement on September 4, 2026, to issue a convertible promissory note ($2.1–$3.6M principal) and warrants to purchase up to 1.3M shares of Class A common stock in a private placement relying on Section 4(a)(2) and Rule 506. The filing explicitly notes the Company must seek stockholder approval to issue in excess of 20% of outstanding shares at a deemed discount to Nasdaq Minimum Price, and the convertible note and warrants are subject to beneficial ownership and exchange caps, indicating substantial dilution. This is a classic private placement of convertible securities with warrant coverage—a dilutive issuance raising capital.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-09-11
The filing discloses the closing of a private placement of 3,750 shares of Series B Convertible Preferred Stock for aggregate proceeds of $3.75 million to five institutional investors. The preferred stock is convertible into common stock at an initial conversion price of $5.24 per share, creating significant dilution potential. This unregistered sale of equity securities under Section 4(a)(2) and Regulation D Rule 506 is a classic dilutive issuance requiring Item 3.02 disclosure.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-09-11
Item 1.01
BioVie entered into an at-the-market (ATM) sales agreement with A.G.P./Alliance Global Partners to issue up to $6.46 million of Class A common stock. This is a classic dilutive equity issuance under an effective S-3 registration statement, allowing the company to raise capital through registered direct sales to the public. The ATM structure and the material offering size make this a dilutive_issuance event.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 75%
filed 2026-09-11
Item 8.01
The filing discloses that recent sales of common stock under an at-the-market offering have triggered a reduction in the exercise price of outstanding Series B Warrants to $1.2046. This reflects dilutive equity issuance activity that materially affects warrant holders and existing shareholders through price adjustment mechanics. While the disclosure is brief and Item 8.01 is used rather than Item 3.02, the substance is a capital raise via ATM offering with warrant repricing consequences.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 95%
filed 2026-09-11
WF International entered into a Share Purchase Agreement on September 10, 2026, to sell 5,000,000 ordinary shares at $1.10 per share in a registered direct offering, expected to raise approximately $5.5 million in gross proceeds. This is a registered equity issuance that will dilute existing shareholders' ownership and voting power, fitting the definition of dilutive_issuance. The disclosure explicitly references the Form F-3 shelf registration statement and prospectus supplement filed with the SEC, confirming this is a registered offering of equity securities.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-09-11
Item 3.02
In connection with the restructuring, New Fortress Energy issued 10,608,922 shares of CoreCo common stock and 2,454,936 shares of CoreCo Mandatorily Convertible Preferred Stock to Plan Creditors, together with 200,000 FLNG 2 Preferred Interests, all issued in reliance on Section 3(a)(10) of the Securities Act. Plan Creditors received 65% of the common equity of 'New NFE' and preferred equity with $2.45 billion liquidation preference, representing a substantial dilutive capital event.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-09-11
Item 1.01
DeFi Development Corp. entered into an at-the-market (ATM) sales agreement with R.F. Lafferty & Co. to offer and sell up to 30,000,000 shares of Variable Rate Series C Perpetual Preferred Stock pursuant to a registered Form S-3, raising capital for general corporate purposes including acquisition of Solana digital assets.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-09-11
Item 1.01
Nautilus Biotechnology entered into an at-the-market (ATM) sales agreement with TD Cowen to sell up to $125 million in common stock under a registered shelf offering, representing a dilutive equity issuance to fund capital needs.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 95%
filed 2026-09-11
EX-99.1
K Wave Media announced a registered direct offering of 526,314 ordinary shares at $1.90 per share for approximately $1.0 million in gross proceeds. This is a direct equity issuance under an effective Form F-3 shelf registration, representing a dilutive capital raise that would materially affect shareholder ownership and the total mix of information available to investors.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-09-11
Item 3.02
P3 Health Partners entered into a Securities Purchase Agreement with CPF affiliates to issue up to $70 million of units consisting of Series D-1 Preferred Stock and warrants to purchase Common Stock under Section 4(a)(2) exemption. The warrants represent a dilutive equity issuance exercisable for approximately 0.66333% of outstanding Common Stock per $1 million funded, constituting a material unregistered private placement.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-09-10
Item 3.02
The Company issued 30,555 shares of Common Stock (7,477 + 23,078) on September 9, 2026, in connection with redemptions of Series A1 and Series A Preferred Stock. This is a dilutive issuance of equity securities in lieu of cash payment, with additional outstanding redemption requests for approximately 22,123 more preferred shares that may be redeemed in Common Stock at the Company's discretion. The conversion price of approximately $4.35 per share and the substantial number of shares issued represent a material capital event typical of Item 3.02 disclosures.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-09-10
Item 3.02
The disclosure details unregistered issuances of 1,448,368 common shares and 202,500 warrants from June 18 through September 4, 2026, which in aggregate exceeded 5% of outstanding shares, triggering Item 3.02 disclosure. These are private placements and warrant exercises relying on Regulation D and Regulation S exemptions, characteristic of dilutive equity issuances at small- to mid-cap companies raising capital through unregistered securities.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 92%
filed 2026-09-10
EX-99.1
This exhibit is a pre-funded warrant agreement for 2,047,668 ordinary shares issued to Hite Hedge Horizon LP under a Securities Purchase Agreement dated August 24, 2026. The warrant has a nominal exercise price of $0.0001 per share, with the aggregate exercise price pre-funded to the Company. This is a classic dilutive issuance structure—an unregistered equity security with minimal exercise price that will result in substantial share dilution upon exercise. The document explicitly notes the securities are not registered under the Securities Act and may only be offered pursuant to exemptions, consistent with private placement activity.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 75%
filed 2026-09-10
Item 8.01
Impinj entered into exchange agreements to issue approximately 188,451 shares of common stock (plus $56.5 million in cash) to holders of convertible notes in exchange for $56.3 million in principal amount of outstanding 2027 Notes. The shares are issued in a private placement under Section 4(a)(2) exemption to qualified institutional buyers. This is a dilutive equity issuance in connection with debt restructuring, though it could also be characterized as debt refinancing; the primary disclosed action is the issuance of equity securities to reduce debt obligations.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 94%
filed 2026-09-10
Item 3.02
Vulcan closed a $39.4 million strategic investment (PIPE transaction) on September 10, 2026, issuing 17,146,190 shares of Class A common stock at $1.71 per share, a $10 million convertible note, and warrants to purchase 1,754,386 shares to an affiliate of Machine Investment Group. The unregistered securities were offered under Section 4(a)(2) and Regulation D exemptions to accredited investors, significantly diluting existing shareholders while strengthening the company's financial position.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-09-10
Item 3.02
CYABRA issued over 59 million shares and warrants through two transactions: an exchange of Series C Preferred Shares for 24.5 million pre-funded warrants and Series A/B warrants, and a conversion of Series A and B Preferred Shares into 9.8 million common shares and 25 million pre-funded warrants. These unregistered sales represent substantial dilution to existing shareholders.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-09-10
Item 1.01
Zedge entered into a Securities Purchase Agreement to sell 2,616,447 shares of Class B common stock and warrants to purchase 2,354,803 additional shares for $7.675 million to insiders including Vice Chairman Howard Jonas and board member Elliot Gibber. The unregistered securities were issued under Section 4(a)(2) and Regulation D exemptions, representing a material private placement with significant dilution to existing shareholders.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 85%
filed 2026-09-10
The filing discloses a prospectus supplement covering the resale of 5,874,094 shares of common stock by selling stockholders under a Form S-3 registration statement. This represents a dilutive equity issuance that increases the float and potential shareholder dilution. The Company is providing legal counsel's opinion on the legality of the shares, which is a standard disclosure mechanism for registered secondary offerings and resales that materially affect the capital structure.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-09-10
The filing discloses conversion of approximately $450,000 of debt into 1,921,441 shares of common stock at an average conversion price of $0.234 per share. Item 3.02 explicitly addresses "Unregistered Sales of Equity Securities" and notes the shares were issued pursuant to Section 3(a)(9) exemption. This is a dilutive equity issuance that increases share count materially and would affect investor assessment of ownership dilution and capital structure.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 85%
filed 2026-09-10
Item 1.01
Ingram Holdco, LLC, the principal stockholder, entered into an underwriting agreement for a secondary offering of 13,125,000 shares of common stock at $27.25 per share, with a 30-day overallotment option for an additional 1,968,750 shares. The Company concurrently repurchased 625,000 shares, partially offsetting but not eliminating the net dilutive effect on existing shareholders' ownership and voting power.
View raw filing on EDGAR →